TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02266407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aquamantys System
Description: The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aquamantys System
Description: The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
Study: NCT04454307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: tramadol 100 mg twice daily for 10 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care delivered in the isolation hospitals.
Description: Oxygen ventilation.
Study: NCT01296607

Intervention type: DRUG
Group type: OTHER
Intervention: Urocortin 2
Description: Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a.

Intervention type: DRUG
Group type: OTHER
Intervention: Urocortin 3
Description: Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a.
Study: NCT04738669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth
Description: The mHealth intervention includes telephonic call and SMS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teach-back
Description: While the teach-back includes counselling session related to discharge instruction including medication adherence.
Study: NCT00559117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-111
Description: A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
Study: NCT03862053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manuka honey
Description: manuka eyedrops applied to the ocular surface

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Manuka honey
Description: manuka eyedrops applied to the ocular surface
Study: NCT00382928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation of pulseless VT/VF by AECD
Description: In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
Study: NCT01052428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol succinate (Toprol XL)
Description: Toprol XL 100 mg once a day for 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100 mg once a day for 2 years
Study: NCT02004275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixazomib
Description: given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: given PO
Study: NCT03283995

Intervention type: OTHER
Intervention: Cardiac Volume Monitoring VolumeView
Description: hemodynamic measure

Intervention type: OTHER
Intervention: Cardiac Volume Monitoring VolumeView
Description: hemodynamic measure

Intervention type: DEVICE
Intervention: echocardiography
Description: hemodynamic measure

Intervention type: DEVICE
Intervention: echocardiography
Description: hemodynamic measure

Intervention type: DEVICE
Intervention: echocardiography
Description: hemodynamic measure

Intervention type: DEVICE
Intervention: echocardiography
Description: hemodynamic measure
Study: NCT02635789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-12G gel
Description: NPC-12G gel is administered topically twice a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: NPC-12G gel placebo is administered topically twice a day for 12 weeks
Study: NCT03043820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: Oral selective estrogen receptor modulator (SERM).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets identical in form and color to intervention.
Study: NCT03012152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard conservative breast surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oncoplastic breast surgery
Study: NCT00597792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NDO Full-thickness Plicator
Description: A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
Study: NCT03090035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon α2
Description: Peg-INF was given in a dose of 180 μg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3
Study: NCT02376439

Intervention type: OTHER
Intervention: Kool-aid
Description: Participant drank two different types of kool-aid (sugar free and regular)
Study: NCT02513940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
Study: NCT02455856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter \[mL\] oral solution on Day 1 and Day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive single dose of itraconazole as 200 mg (2\*100 mg capsule) from Day 2 to Day 6.
Study: NCT01407978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval P monovalent influenza vaccine
Description: * Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with Fluval AB
Description: * Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with Fluval AB Novo
Description: * Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose.
Study: NCT04366583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: argon plasma coagulation
Description: Olympus electrosurgical unit/argon plasma coagulation unit (PSD-60/Endoplasma, Olympus Corp., Tokyo, Japan)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hemoclipping
Description: clipping device (Olympus HX 110/610, Olympus Corp., Tokyo, Japan)
Study: NCT04116697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
Study: NCT04169412

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Blood Gas Analysis using Stat Profile pHOx® Series (nova biomedical, Waltham, U.S.) and Enzym-linked Immunosorbent Assay (ELISA) using Bio-Rad (Bio-Rad Laboratories, California, U.S.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Blood Gas Analysis using Stat Profile pHOx® Series (nova biomedical, Waltham, U.S.) and Enzym-linked Immunosorbent Assay (ELISA) using Bio-Rad (Bio-Rad Laboratories, California, U.S.)
Study: NCT03834259

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sitting position
Description: keeping the patient in a sitting position after spinal anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supine position
Description: keeping the patient in supine position after spinal anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supine position
Description: keeping the patient in supine position after spinal anaesthesia
Study: NCT02080728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 500mg/100ml Naropeine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride BAXTER
Study: NCT02883933

Intervention type: OTHER
Intervention: Data collection
Study: NCT05889000

Intervention type: OTHER
Intervention: questionnaire responses
Description: questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)

Intervention type: OTHER
Intervention: questionnaire responses
Description: questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
Study: NCT02513940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
Study: NCT04171310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442168
Description: Pharmaceutical form:oral solution Route of administration: Oral
Study: NCT01818310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A: Intramuscular
Description: Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B: Intraarterial
Description: Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group C: Intravenous
Description: Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group D: Surgical endovascular treatment with maximum medicamentous treatment
Description: Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
Study: NCT00965328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH 4 to 2 L/h
Description: CVVH is initiated at 4L/h and is converted to 2L/h after 60 min

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH 2 to 4L/h
Description: CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
Study: NCT00721890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Double-Brewed Green Tea
Description: liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
Study: NCT02266862

Intervention type: RADIATION
Intervention: Study group
Description: Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
Study: NCT02513940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Study: NCT02318108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentored organizational change
Description: Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
Study: NCT02513940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo transdermal gel and placebo (lactose) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo transdermal gel and placebo (lactose) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo transdermal gel and placebo (lactose) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo transdermal gel and placebo (lactose) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo transdermal gel and placebo (lactose) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo transdermal gel and placebo (lactose) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
Study: NCT02318108

Intervention type: OTHER
Group type: OTHER
Intervention: Education only
Description: Practices are given basic education related to population-based care and are given feedback on performance.
Study: NCT01531803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kedbumin 25%
Description: Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin).
Study: NCT02513940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
Study: NCT02349230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Astym treatment
Description: Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Astym treatment
Description: Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
Study: NCT00129714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical collar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Study: NCT05671120

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcutaneous levator recession
Description: recession of the upper and lower eyelid retractors can improve the upper eyelid contour if the patient has lateral flare (common in TED). The choice of procedure depends on severity of lid retraction and associated features like proptosis, status of extraocular muscles, and corneal condition
Study: NCT00537823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT04080076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar 80 UNT/ML Injectable Solution
Description: ACTHar 80 Units SQ 1042 x Week
Study: NCT00537823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study: NCT03043365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control fish oil
Description: 4 capsules, 3 times a day after meals
Study: NCT01531803

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Solution
Description: Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
Study: NCT01064960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips MR-guided HIFU system
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
Study: NCT03255733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Therapeutic Ultrasound Treatment